You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

CLINICAL TRIALS PROFILE FOR OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT03124199 ↗ Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection Completed Fundación de Investigación Biomédica - Hospital Universitario de La Princesa Phase 3 2014-02-01 Background: A progressive decrease in Helicobacter pylori eradication rates has been described over the years, so new combinations of antibiotics for treatment are needed. Aim: To evaluate the efficacy and safety of the addition of rifaximin to standard triple therapy (omeprazole, amoxicillin and clarithromycin) for the eradication of H. pylori. Methods: Independent prospective pilot clinical trial (EUDRA CT: 2013-001080-23). Forty consecutive adult patients were included with H. pylori infection, dyspeptic symptoms and naive to eradication treatment. A full blood test was performed in the first 5 patients included to evaluate the safety of the treatment. H. pylori eradication was confirmed with urea breath test at least 4 weeks after the end of treatment. Treatment: Rifaximin 400 mg/8 h, clarithromycin 500 mg/12 h, amoxicillin 1 g/12 h, and omeprazole 20 mg/12 h for 10 days.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002682 ↗ Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach Completed National Cancer Institute (NCI) Phase 2 1995-08-10 RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00002682 ↗ Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach Completed M.D. Anderson Cancer Center Phase 2 1995-08-10 RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00003151 ↗ Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma Completed University of Glasgow Phase 2 1997-09-01 RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

Condition Name

Condition Name for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Intervention Trials
Helicobacter Pylori Infection 13
Non-alcoholic Fatty Liver Disease 3
Helicobacter Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Intervention Trials
Helicobacter Infections 13
Infections 6
Infection 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

Trials by Country

Trials by Country for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Location Trials
United States 5
Spain 4
Iran, Islamic Republic of 4
Pakistan 3
United Kingdom 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Location Trials
Texas 3
Missouri 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

Clinical Trial Phase

Clinical Trial Phase for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Clinical Trial Phase Trials
Phase 4 13
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Clinical Trial Phase Trials
Completed 22
Unknown status 8
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

Sponsor Name

Sponsor Name for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Sponsor Trials
Tehran University of Medical Sciences 4
Dow University of Health Sciences 1
Universidad del Valle, Colombia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
Sponsor Trials
Other 49
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.